Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Neoplasms
  • Sesquiterpenes

abstract

  • Given the results of this study, the recommended dose of irofulven is 10.64 mg/m(2) as a 5-minute IV infusion daily for 5 days every 4 weeks. The preliminary antitumor activity documented in a patient with advanced pancreatic cancer and the striking preclinical antitumor effects of irofulven observed on intermittent dosing schedules support further disease-directed evaluations of this agent on the schedule evaluated in this study.

publication date

  • December 15, 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2000.18.24.4086

PubMed ID

  • 11118470

Additional Document Info

start page

  • 4086

end page

  • 97

volume

  • 18

number

  • 24